AQR Capital Management LLC Acquires 21,980 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

AQR Capital Management LLC raised its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 196.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 33,164 shares of the biopharmaceutical company’s stock after buying an additional 21,980 shares during the quarter. AQR Capital Management LLC’s holdings in Agios Pharmaceuticals were worth $1,430,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at $37,000. Quest Partners LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $40,000. North Star Asset Management Inc. bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $216,000. XTX Topco Ltd bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $230,000. Finally, Northcape Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $244,000.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $41.82 on Friday. The firm has a 50-day simple moving average of $44.62 and a two-hundred day simple moving average of $40.41. The company has a market cap of $2.37 billion, a P/E ratio of -6.62 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a fifty-two week low of $19.80 and a fifty-two week high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.51) EPS. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AGIO. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $52.20.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.